TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $166 | -59.7% | 18,596 | -30.6% | 0.01% | -60.6% |
| Q2 2023 | $412 | -1.2% | 26,794 | +44.6% | 0.03% | +10.0% |
| Q1 2023 | $417 | +18.5% | 18,532 | +10.6% | 0.03% | +3.4% |
| Q4 2022 | $352 | -99.9% | 16,751 | +18.4% | 0.03% | -9.4% |
| Q3 2022 | $349,000 | -3.6% | 14,145 | -5.4% | 0.03% | -3.0% |
| Q2 2022 | $362,000 | +76.6% | 14,954 | +88.1% | 0.03% | +371.4% |
| Q1 2022 | $205,000 | – | 7,951 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |